Welcome to the Newsroom
19 April 2017
Prima BioMed Receives Approval for Third Cohort of Phase I Melanoma Trial
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) today announced that approval has been granted for the third cohort of its Phase I clinical trial for IMP321 in combination with KEYTRUDA® being conducted in Australia. The third cohort will recruit six patients with unresectable or metastatic melanoma.
Article as pdf